The RESOLVE project, funded by the EU with 8 million euros over five years, aims to establish the optimal therapy for two common forms of blood cancer: acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL). Led by the Instituto de Investigaciones Biomédicas de Salamanca, the project involves a consortium of 21 partners from 8 countries.
The project focuses on using the diagnostic test “measurable residual disease” (MRD) as a personalized diagnostic tool to determine the most effective treatment for individual patients. MRD, which detects leukemic cells undetectable by traditional methods such as microscopy, will guide personalized treatment recommendations. Leveraging existing expert networks and partnerships with patient participation, the consortium aims to establish MRD as a biomarker to guide the treatment of chronic myeloid leukemia and chronic lymphocytic leukemia across Europe.
The goal is to use MRD to tailor treatments, potentially making intensive therapies such as stem cell transplants unnecessary for some patients and shortening treatment times for others. This approach could improve patients’ quality of life and reduce treatment costs.
The project involves rigorous clinical studies in 60 hospitals to develop standards for the harmonized use of MRD technology. The aim is to introduce MRD assessment as the gold standard for personalized leukemia treatment across Europe, using existing infrastructures and the expertise of European research networks.
Ultimately, the RESOLVE project is aligned with the EU Cancer Mission funding line, which seeks to improve the lives of more than three million people with cancer by 2030. Along with the Biomedical Research Institute of Salamanca, 20 other institutions and 60 hospitals from several European countries are involved in the project.
More information about the RESOLVE project can be found here.
